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Abstract
An ingenious system evolved to facilitate insulin binding to the insulin receptor as a monomer and at the same time ensure
sufficient stability of insulin during storage. Insulin dimer is the cornerstone of this system. Insulin dimer is relatively weak,
which ensures dissociation into monomers in the circulation, and it is stabilized by hexamer formation in the presence of
zinc ions during storage in the pancreatic b-cell. Due to the transient nature of insulin dimer, direct investigation of this
important form is inherently difficult. To address the relationship between insulin oligomerization and insulin stability and
function, we engineered a covalently linked insulin dimer in which two monomers were linked by a disulfide bond. The
structure of this covalent dimer was identical to the self-association dimer of human insulin. Importantly, this covalent dimer
was capable of further oligomerization to form the structural equivalent of the classical hexamer. The covalently linked
dimer neither bound to the insulin receptor, nor induced a metabolic response in vitro. However, it was extremely
thermodynamically stable and did not form amyloid fibrils when subjected to mechanical stress, underlining the importance
of oligomerization for insulin stability.
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Introduction
Insulin, a small peptide hormone, is crucial in maintaining
blood glucose homeostasis. Defects in insulin secretion and action
result in diabetes mellitus, a severe metabolic disorder, which
untreated will lead to serious health problems and ultimately death
[1]. Insulin consists of 51 amino acids in two peptide chains, the A-
and the B-chain. It contains six cysteine residues (Cys) forming
three disulfide bonds, two of them link the two chains and one
intra-chain bond is found in the A-chain [2]. Insulin is expressed in
the pancreatic b-cells of the islets of Langerhans [3]. At
micromolar concentrations it self-associates into dimers. This
concentration is found during expression in the b-cells and there
are indications that dimers are formed in the ER during expression
[4,5]. The positions present in the dimer forming surface are all
located in the B-chain and involve residues: B8, B9, B12, B13,
B16, and B23–B28 [2,6]. At millimolar concentration in the
presences of zinc ions, insulin further associates into hexamers [7].
When blood glucose levels are low, insulin is stored as hexamers in
vacuoles of the b-cells. In response to elevation of blood glucose
levels, the hexamers are released into the blood where they
dissociate into dimers and monomers [8]. Insulin mediates its
effect through the insulin receptor [9]. The insulin receptor is
found as a homo-dimer and it is believed that two separate
monomers bind to the receptor. It is believed that the function of
dimer and hexamer formation lies in stabilisation of the molecule
during storage [10,11].
Dimerization using disulfide bonds is a common strategy for
protein stabilisation often found in nature [12–14]. Introduction of
Cys in the dimer forming surface of a protein can lead to the
formation of disulfide-bridged dimers [15–21]. Crystal structures
(ex. PDB code 1mso) of human insulin dimers reveals that residues
in positions B12, B13, B24, B25 and B26 in one monomer are
found in close proximity to their complementary position in the
second monomer (Ca to Ca distance ,10 A˚) (Figure S1) but only
the distance between the two B25 residues is below 6.5 A˚ which is
ideal for disulfide bond formation [22]. We have previously
observed that introduction of a Cys in position B25 results in
exclusive expression of a covalent dimer insulin precursor (see
experimental section) whereas substitution of other positions in the
dimer surface with Cys led to negligible or no expression of insulin
precursors [23]. The B25C position is therefore a unique position
in insulin with respect to dimer formation.
In this article, we report structural and functional properties of
this B25C covalently linked dimer (B25C-dimer) in comparison to
human insulin and discuss the balance between oligomerization
and receptor binding.
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Methods
Plasmids construction and expression
Material, vector, strain and construction were as previously
described [24–27]. Briefly, the mutation to a Cys was introduced
in the insulin coding sequence by overlapping PCRs [28] in the
selected position. The insulin precursor is expressed in Saccharo-
myces cerevisiae and secreted as a proinsulin-like single-chain
consisting of a spacer Glu-Glu-Ala-Glu-Ala-Glu-Ala-Pro-Lys
(EEAEAEAPK) [25] followed by the B-chain (B1–B29) linked
to the A-chain (A1–A21) by a mini C-peptide Ala-Ala-Lys (AAK)
[29]. The expression yield of the insulin precursor were
determined by reversed-phase high-performance liquid chroma-
tography (RP-HPLC) based on peak area using human insulin as
external standard. The was mass determined by liquid chroma-
tography/mass spectrometry (LC/MS) as previous described
[23].
Purification
A 3 L batch of the B25C precursor was fermented in shaking
flasks. The cell-free culture supernatant was acidified and the
precursor was partially purified and concentrated by a capture step
using ion exchange chromatography. The precursor was enzy-
matically digested to remove the spacer and C-peptide, the digest
was stopped after several days and the conversion verified by LC/
MS. The dimer was further purified by RP-HPLC and
lyophilized.
Construction of the B25C alkylated monomer
Partially purified dimer using ion exchange chromatography
was concentrated 10 times by lyophilisation and subsequent
dissolution in water to a concentration of 1.5 mg/ml. Tris(2-
carboxyethyl)phosphine (TCEP) immobilized on agarose gel
(Thermo Scientific) was equilibrated in elution buffer (from cation
exchange chromatography) mixed 1:1 with 1 M NaOAc (sodium
acetate) pH 5.5. The liquid was removed from 3 ml TCEP slurry
and the concentrated solution with the dimer precursor was
added. The sample was incubated over night with slow mixing,
just fast enough to ensure gel suspension. 100 ml 10 mM N-ethyl
maleimide (NEM) in water was added and set to react for 1 hour
with turning. The samples were separated from the TCEP gel by
centrifugation and the two B25C-NEM monomeric isomers were
purified by RP-HPLC. The fractions for each isomer were pooled
and concentrated using a speed vac.
Pulse-chase
The experiment was carried out essentially as described before
[25]. Briefly, cultures with OD600 of approximately 12 in media
without Cys and Met were pulsed with 30 mCi [35S]cysteine(Per-
kinElmer) for 2.5 min followed by removal of the labelled Cys.
Media containing 18.5 mM un-labelled Cys and Met were added
equal to 5.5 min after the start of pulsing and the sample was
taken. Immediately afterwards, protein synthesis was stopped
using 1 ml 5% sodium azide. The cells were spun down and
separated from the supernatant. The samples were then frozen at
220uC until further analyses.
Analyses of the samples were performed by SDS-PAGE. The
cells were lysed and the cell lysate and the supernatant was applied
to a SDS-gel (10% Bis-Tris, Invitrogen) either untreated or
following treatment with PNGase F (Biolabs) for 30 min at 37uC.
The gels were fixed, dried and then exposed to a phosphor screen
and scanned in a phosphor imager (Typhoon 9410, Variable
Mode Imager, GE Healthcare).
Crystal structure
Crystals were grown by the sitting drop vapour diffusion
method. 1 ml of protein solution containing 4.6 mg/ml of the
insulin analogue was mixed with 1 ml of reservoir solution
containing 0.1 M Bis- Tris pH 6.5 and 3.0 M NaCl. Crystals
with dimensions of about 0.1 mm were obtained within 1 week.
The crystal used for data collection was soaked in 15% ethylene
glycol prior to freezing in liquid nitrogen. Data were collected in
house using a rotating anode (Rigaku MicroMax-007HF, Cu/Ka
radiation, l= 1.5418 A˚) and a Rayonix SX-165 CCD detector
(Mar Research, Hamburg) at a temperature of 100 K. The data
were indexed and scaled with the HKL2000 package. The
structure was solved by molecular replacement method using
MOLREP [30] with an in house insulin monomer as search
model. The structure was refined in Refmac [31], atom
coordinates were manually adjusted in Coot [32]. Water molecules
were added using the ‘Find water’ algorithm in Coot. Data
collection details and refinement statistics are summarized in
Table 1. Coordinates with structure factors have been deposited to
the Protein Data Bank (PDB) with the accession code 3U4N.PDB
Analytical Ultracentrifugation
Analytical Ultracentrifugation (AUC) experiments were per-
formed with a BeckmanCoulter XL-I analytical ultracentrifuge
(Indianapolis, IN), using the interference optics of the instrument.
Samples were filled in sapphire-capped two-sector Epon-centre-
pieces of 12 mm optical pathlength. The B25C-dimer was
dissolved in and dialysed against buffer containing 50 mM sodium
chloride, 10 mM Tris at pH 7.4. The dialysate was used for
dilution and optical referencing. All experiments were conducted
at 20uC and with multiple concentrations of the peptide, prepared
by 7-fold serial dilution. Sedimentation Velocity (SV) experiments
were performed at 48 krpm and analysed with either the c(s)-
algorithm [33] as implemented in SEDFIT v11.8 or by the time-
derivative method [34], as implemented in DCDT+ v2.3.1.
Sedimentation Equilibrium (SE) experiments were performed at
sequentially 15, 24 and 36 krpm and attainment of apparent
hydrodynamic and thermodynamic equilibrium was ascertained
with MATCH. Water blanks for each cell and speed were
recorded immediately after the experiment and subtracted from
the raw data before analysis. SE data were globally fitted to
multiple models of reversible self-association with NONLIN [35]
and the best-fit model selected based on a minimised variance and
visual inspection of the residuals run pattern. SV experiments of
the B25C-dimer in the presence of Zn2+ were performed at a
constant concentration of peptide of 75 mM and different
concentrations of Zn2+. The ratio of [Zn2+]/[B25C-dimer] was
adjusted to the concentration of insulin monomer normals, i.e. one
mole of B25C-dimer is two normal with respect to insulin
monomers. The partial specific volume v¯ of the B25C-dimer and
the density r of the buffer were measured with a digital
densitometer DMA5000M from AntonPaar (Graz, Austria), the
viscosity g of the buffer was calculated from composition using
SEDNTERP.
Receptor binding assay
Receptor binding was measured by an IR competition binding
assay performed on the A isoform of the insulin receptor in a
scintillation proximity assay (SPA) as previously described [24].
Briefly, binding competition of the B25C-dimer and [125I]TyrA14-
labelled insulin (Novo Nordisk A/S) in the SPA assay was used to
determine binding receptor affinities. A human standard (n = 4)
and the dimer (n = 4) were tested in one plate. The data was
analysed according to a four-parameter logistic model [36] and the
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affinities were expressed relative to a human insulin standard
[IC50(insulin)/IC50(analogue)6100%].
Metabolic potency determination
The metabolic potency was determined by lipogenesis essentially
as described before [37,38]. Shortly, isolated primary rat
adipocytes were shaken vigorously for 1 h at 37uC. Aliquots of
100 mL were distributed in 96-well PicoPlates and incubated 2 h at
37uC with gentle shaking together with 10 mL glucose solution
containing D-[3-3H]glucose and glucose and 10 mL of increasing
concentration of HI (for reference) or B25C-dimer. The incubation
was stopped with addition of 100 mL MicroScint E (Packard) and
the plates were counted in a TopCount NXT (PerkinElmer Life
Science). The data were analyzed according to a four-parameter
logistic model [36] and the metabolic potency was expressed
relative to a HI standard [EC50(insulin)/EC50(analogue)6100%].
DSC
The differential scanning calorimetry (DSC) measurements
were performed essentially as described before [11]. The insulin
analogues were formulated at 0.2 mM in a 2 mM phosphate
buffer at pH 7.5 which was also used as reference buffer. The
samples were heated from 10uC to 110uC with a scan rate of 60uC
per hour.
ThT fibrillation assay
Samples were prepared freshly before each assay. Thioflavin T
(ThT) (Sigma) was added to each sample from a concentrated
stock solution in water to a final concentration of 1 mM. Four
aliquots of 200 ml from each sample were placed in a 96 well
microtiter plate (Packard OptiPlateTM-96, white polystyrene). The
plate was sealed with Scotch Pad (Qiagen). The assay was
performed using a Fluoroskan Ascent FL fluorescence plate reader
(Thermo). The temperature was adjusted to 37uC and the orbital
shaking was adjusted to 960 rpm (1 mm amplitude). Fluorescence
measurements were done using 444 nm and 485 nm excitation
and emission filters, respectively. The plate was incubated for
10 min without shaking prior to the first measurement and then
measured every 20 minutes for 45 hours. Between each measure-
ment, the plate was continuously shaken and incubated as
described. The background fluorescence emission from ThT in
the absence of amyloid fibrils was negligible and thus no
background correction was done. Each shown time point is the
mean of the four replicas with standard deviation error bars. Only
data obtained in the same experiment (i.e. samples on the same
plate) are presented.
Insulin concentrations were determined by RP-HPLC methods
using an insulin standard as a reference. After completion of the
ThT fibrillation assay pools were made by recollecting 150 ml from
each replica. These pools were centrifuged at 30,000 g for
40 minutes. The supernatant was filtered through a 0.22 mm filter
and the concentration of insulin remaining in solution determined
by RP-HPLC analysis.
Results
Expression of the B25C-dimer
RP-HPLC analyses of HI and the B25C-dimer fermented under
the same conditions showed that the B25C-dimer had an
expression yield of 108% (n = 3, SD = 1.98%) relative to that of
HI (based on UV absorbance of HI). LC/MS analyses of the
fermentations showed that the B25C precursor was present solely
as a dimer, which was observed only for this precursor in the Cys
scan of insulin [23]. A small second peak (,4% of total) with equal
mass to the B25C- dimer precursor was also observed and may
represent another conformation either in form of disulfide
scrambling, alternative folding, etc. (Figure S2).
Pulse-chase experiments were used to investigate the point of
dimer formation. Disulfide bonds are readily formed in the
oxidizing environment found in the cellular compartments of the
secretory pathway [39]. Also, during expression in yeast the
concentration is high enough for dimer formation [40]. Thus, if
the insulin self-associates to dimers bringing the two B25 Cys in
proximity to each other this allows for disulfide bond formation.
The pulse-chase experiments showed the presence of the
covalent dimer in cells demonstrating that the formation occurs
during expression (Figure S3). This gives strong indications that
HI forms dimers during expression in yeast as proposed by
Kjeldsen [40].
Table 1. Data collection and refinement statistics.
Data processing statistics
wavelength (A˚) 1.5418
Space group I213
cell axis a, b, c (A˚) 77.9
cell angles (deg) a b c 90
temperature (K) 100
diffraction limit (A˚) 1.98
no. of observations 38677
unique reflections 5631
highest resolution shell (A˚) 2.01-1.98
completeness
all data (%) 99.3
high. resolut. shell (%) 85
Rmerge
a
all data (%) 6.7
high. resolut. shell (%) 25.8
Refinement statistics
resolution range (A˚) 31.8-1.98
no. of reflections 5334
R value (%) b 16.7
Rfree value (%)
b 21.7
highest resolution shell (A˚) 2.03-1.98
no. of reflections 316
completeness (%) 89.8
R value (%)b 18.0
Rfree value (%)
b 29.4
r.m.s.d.c
bond length (A˚) 0.022
bond angles (deg) 2.417
average B-factor (A˚2) 23.1
aRmerge =S|Ii2I|/SI where Ii is an individual intensity measurement and I is the
mean intensity for this reflection.
bR value = crystallographic R-factor =S|Fobs|2|Fcalc|/S|Fobs|, where Fobs and Fcalc
are the observed and calculated structure factors respectively. Rfree value is the
same as R value but calculated on 5% of the data not included in the refinement.
cRoot-mean-square deviations of the parameters from their ideal values.
doi:10.1371/journal.pone.0030882.t001
Novel Covalently Linked Insulin Dimer
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30882
Purification of the dimer
The B25C-dimer precursor was fermented, partially purified
and up-concentrated using ion exchange chromatography. Insulin
precursors are quickly converted into mature insulin analogues by
removal of the spacer and C-peptide by enzymatic digestion.
However, as the C-peptide was only slowly removed from the
B25C-dimer, it was necessary to digest for several days. Under
these harsh conditions large amounts of a by-product were also
generated (Figure S4). The B25C-dimer was further purified by
RP-HPLC and lyophilized.
The covalently linked dimer versus non-covalent human
insulin dimer
The structure of the B25C-dimer was determined by X-ray
crystallography and refined to a resolution of 2.0 A˚. The crystals
belonged to the cubic space group I213 with cell dimensions
a = b = c = 77.9 A˚ with one monomer in the asymmetric unit. The
unit cell axes were ,1 A˚ shorter compared to a typical cubic
insulin crystal [41,42]. The dimeric structure was formed by
applying appropriate symmetry operations. The crystal structure
(Figure 1) reveals that disulfide bonds were formed correctly with
no disulfide scrambling and the two monomers were linked via a
new disulfide bond formed between the introduced Cys in position
B25 of each monomer. The crystal structure of the B25C-dimer
resembled that of porcine insulin (B30TRB30A compared to HI,
PDB code 1B2E) crystallized in the same space group). A
structural alignment of the two structures yields an RMSD of
0.20 A˚ (all Ca) with the largest deviation found at position B21E.
The backbone of the B-chain C-terminus is slightly shifted relative
to the 1B2E structure. This is most likely caused by a small
difference of the B21E position and its effect on the crystal packing
interaction with the C-terminal part of the B chain in a symmetry
related molecule. The residues close to the additional disulfide
bond (B23–B28) had an RMSD value of 0.39 A˚ (Ca). The
distance, between adjacent B25 positions in the two monomers
forming a dimer, increased by 0.3 A˚ in the B25C-dimer. Overall,
no significant conformational perturbations caused by the
introduction of the additional disulfide bond at position B25
could be observed.
Self-association of the B25C-dimer. AUC was used to
investigate the B25C-dimer self-associating abilities and compared
to those of known oligorimization of HI. SV experiments showed
that the B25C-dimer had a typical pattern for a reversible self-
association, qualitatively similar to HI, (Figure S5,A). SV
measured at constant peptide concentration and increasing
[Zn2+]/[B25C-dimer] from 0 to 6 showed formation of larger
oligomers. At [Zn2+]/[B25C-dimer] ratios of 2 and 3, the
oligomers in solution were almost exclusively trimers of the
B25C-dimer (analogous to hexamers of monomeric insulin,
Figure 2,A). This was indicated by an average molar mass of the
macromolecular compound close to that expected for a trimer and
values for the diffusion and sedimentation coefficients are in
agreement with published values for hexameric insulins of various
origins, (Table 2). Increasing the [Zn2+]/[B25C-dimer] ratios
resulted in even higher oligomeric species. This behaviour again
resembles that of HI (Figure S5,B), confirming the high
resemblance of the B25C-dimer to HI in respect to its self-
association ability.
The equilibrium coefficient for the dimer formation of B25C-
dimers was measured by sedimentation equilibrium experiments
and the results indicated monomer-dimer equilibrium with KD1–2
of 1.3261024 [M], (Figure 2,B). This coefficient for the formation
of dimers of the B25C-dimer (corresponding to insulin tetramers)
is of the same order of magnitude as observed for formation of
both the classic dimer surface and dimer formation through the
hexamer surface when calculated based on an indefinite
duoisodesmic association model (indefinite monomer on monomer
association) of insulin [43,44].
In vitro activity. The B25C-dimer was investigated with
regard to its binding affinity to the receptor in a receptor binding
competition assay. The dimer was found to bind with markedly
decreased affinity compared to HI (IC50 = 0.0012% relative to HI
in the same plate, n = 3, SD = 0.00008%), (Figure 3A). The B25
position is important for receptor binding [45,46] and to
investigate if the decrease in binding affinity was caused by the
substitution of Phe in position B25 with Cys a monomeric form of
the analogue was constructed. The B25C-dimer precursor was
reduced using immobilized TCEP and subsequently alkylated with
NEM. The alkylation step was necessary to protect the free thiol
on the B25 Cys from disulfide scrambling during the assay, which
was performed at physiological pH. The introduction of the NEM
moiety resulted in two stereoisomers of B25C-NEM [23], which
gave rise to two isolated peaks in the LC analysis. Both forms of
the monomer were purified and tested separately in the receptor
assay. There was no difference in the binding affinity of the two
Figure 1. Cartoon representation of the crystal structure of the
B25C-dimer. A: The A chain is coloured in green and the B chain is
shown in blue. The additional disulphide bond is shown by stick
representation (yellow). An omit map was calculated by omitting the
Sulphur atom of B25C. The resulting difference electron density Fo-Fc
map is coloured in orange at s-level = 3.0. It is clear from the structure
that the two monomers are linked by a disulfide bond between the two
adjoining B25C. B: Comparison of the B25C structure (blue) with that of
the porcine in-sulin (PDB code 1B2E) (grey). The Ca trace shows that the
two structures have a high resemblance with minor deviations in Ca
positions at residue B21E and B29K.
doi:10.1371/journal.pone.0030882.g001
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isomers (B25C-NEM1:IC50 = 0.35%, SD = 0.015% and B25C-
NEM2:IC50 = 0.34%, SD = 0.029% relative to HI in the same
plate, n = 3), (Figure 3A). The binding of the B25C-monomer was
therefore more than 250 times stronger than that of the B25C-
dimer. We thus concluded that the mutation of the Phe to a Cys
was not the main cause of the low affinity of the dimer.
The ability of the B25C-dimers to elicit a metabolic response
was tested in a lipogenesis assay. The results reflect those seen in
the receptor assay with EC50 values 0.003% (relative to HI in the
same plate, n = 3, SD = 0.0003%), (Figure 3B). This indicates that
the low binding measured in the B25C-dimer assay was not
unspecific as an in vitro response was seen in the same range as the
binding affinity.
Stability. The thermodynamic stability of the B25C-dimer
compared to HI was investigated by DSC. The excess heat
capacity (Cp) of the samples compared to a reference buffer is
shown in the thermograms, (Figure 4A). The transition midpoint
(taken as the maximum of the thermograms) of the melting curve
(Tm) for the B25C-dimer (Tm = 102.8uC) was increased by 38.9uC
when compared to HI (Tm = 63.9uC). Huus et al. [11] have
Figure 2. AUC results for the B25C-dimer. A: SV Analysis of the
B25C-dimer in the presence of 2 Zn2+/hexamer (insulin normals). In the
top part of the figure, open circles represent the g(s*)/s-curve derived
from a dcdt-analysis. For clarity, only every 10th data point is shown. The
solid red line represents the fit to a model of a single ideal species,
resulting in the parameters shown in Tabel 2. The bottom part of the
figure represents the local deviations between the experimental and
simulated data (residuals). Every data point is shown. The rmsd of the
shown fit is 9.8361023. B: Representative data of a SE experiment used
to determine the self-association model of B25C. In the top part of the
figure, open circles represent experimental concentration distributions
at apparent thermo- and hydrodynamic equilibrium for one concen-
tration (out of five) at 15 krpm (black), 24 krpm (red) and 36 krpm
(green). For clarity, only every 10th data point is shown. The solid like-
colored lines represent the global fit to all measured conditions to a
model of a reversible monomer-dimer model, resulting in the
equilibrium coefficient mentioned in the text. The bottom part of the
figure represents the local deviations between the experimental and
simulated data (residuals). Every data point is shown. The molar mass
parameter was fixed to its expected value and the global rmsd of the fit
is 7.461023.
doi:10.1371/journal.pone.0030882.g002
Table 2. The experimental parameters determined from the fit in Figure 2 and results previously determined for hexameric insulin
of human and porcine origin.
Sample
Standard Sedimentation
Coefficient s20,w, [S]
Standard Diffusion Coefficient
D20,w, (61027 [cm
2/s])
Molar mass
[kg/mole] Rh [nm]
B25C-dimer 3.24* 9.01* 35.56* 2.38
HI [65]** 3.02* 7.93 34.85 2.75
Bovine insulin [66] 3.12 8.35* 34.4 2.63
Porcine insulin [67] 3.09 8.17* 34.67 2.7
*Measured value., **Probably affected by non-ideality because of high concentration.
doi:10.1371/journal.pone.0030882.t002
Figure 3. Measurements of in vitro activity of the B25C-dimer
compared to HI. A: Representative insulin receptor binding curves for
HI(black), B25C-NEM1 (dark gray) B25C-NEM2(gray)and the B25C
dimer(light gray). B: Representative metabolic dose response curves
for HI(black) and the B25C-dimer (dark gray). Each point on the graph
represents the mean 6 SD, n = 4 within one assay.
doi:10.1371/journal.pone.0030882.g003
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previously shown with a combination of DSC and circular
dichroism that thermal denaturation of the monomer proceeds
through a non-two-state transition with an intermediate, whereas
the insulin hexamer formed in the presence of zinc ions (Zn2+)
proceeds through a two-state transition where the denaturation of
the monomer occurs instantaneously following dissociation of the
hexamer. Addition of zinc ions to HI resulted in hexamer
formation which caused an increase in the Tm of HI to 84.8uC as
demonstrated before [11]. When zinc ions were added to the
B25C-dimer an increase was also observed to even higher extend
with a Tm well above 100uC. Above the transition temperature
rapid aggregation and precipitation was indicated by a steep
exotherm. Denaturation of the dimer was not reversible and it was
not possible to calculate thermodynamic parameters. Acetic acid
(HOAc) has been shown to promote dissociation so that insulin is
found predominantly in its monomeric form [47]. The B25C-
dimer dissolved in 20% HOAc displayed an endothermic peak
with a subsequent baseline making it possible to calculate
thermodynamic parameters. The thermogram for the B25C-
dimer in 20% HOAc fitted well to a non-two-state transition
model which indicates that intermediary states are present. The
calorimetric enthalpies (DH) were obtained for the dimer in 20%
HAc and HI at pH 7.4 with and without zinc. The stability of the
B25C-dimer (132.4 kJ/mol; mol refers insulin normals) was
markedly increased compared to HI (87.8 kJ/mol). With the
addition of zinc ions to HI the enthalpy increases to 145.4 kJ/mol
which is only slightly more than the B25C-dimer at acetic pH. The
Tm of the dimer in 20% HOAc had decreased to 77.9uC
compared to the neutral pH. It is unclear whether the acidic pH
only influences the oligomerization or whether it affects the
thermodynamic stability of the B25C dimer molecule as well. It
has been shown that insulin in 20% HOAc retains a native like
structure [47], but it is likely that the low pH causes changes of
charge states resulting in a decrease in stability.
Even though insulin is a relatively stable protein because of its
tight conformation caused by the three disulfide bonds [2], it still
has flexible areas mainly in the C- and N-terminals of the B-chain.
One of the largest physical stability issues with insulin is fibrillation
which is thought to be initiated by unfolding of the C-terminal end
of the B-chain [48]. The propensity of the B25C-dimer to form
amyloid fibrils was compared to HI in a ThT fibrillation assay,
(Figure 4B). HI fibrillated fast within the first hour of incubation at
37uC with vigorous shaking, but remarkably no fibrillation of the
dimer was observed within 45 hours. Furthermore, after comple-
tion of the ThT fibrillation assay the concentration of B25C-dimer
in solution was unchanged whereas all HI was lost from solution
due to amyloid fibril formation (data not shown).
Discussion
In the crystal structure of HI the two B25 positions are located
in the C-terminal b-sheets of the respective B-chains just opposite
each other with a distance suitable for disulfide bond formation
(Ca to Ca distance ,6.5 A˚) [22]. Introduction of a Cys in position
B25 resulted in expression of a dimeric precursor. A disulfide bond
linking the two Cys, one from each insulin molecule, was clearly
visible in the electron density map from the crystal structure
analysis. AUC analyses showed that the B25C-dimer oligomeri-
zation pattern resembled that of HI and that it was capable of
forming analogous hexamers in the presence of zinc ions.
Insulin has a complex oligomerization pattern which stabilizes
the protein during storage. Other proteins favour covalent
dimerization through disulfide formation [12–14]. To assess the
reason for the highly evolved oligomerization pattern of insulin,
the B25C-dimer was used to investigate the effect of the first
oligomeric state on insulin’s activity and stability.
The expression yield of an analogue reflects its stability and the
yeast cells ability to fold it [40,49]. Chaperones are known to play
an important role in nascent protein stabilization and folding [5].
Similar to chaperones, insulin oligomerization during expression
could play an important role for the ability of the yeast cells to
export it into the supernatant [40]. It could be argued that
dimerization also causes higher stabilisation during expression
compared to the monomeric form. It would therefore be expected
that the expression yield of the B25C-dimer be higher than that of
HI if this was present as a monomer during expression. The fact
that the expression yields of both insulin analogues are similar
indicates that HI is present as a dimer during expression in yeast.
Until now it has been speculated that insulin associates into dimers
in the ER, as it was estimated that the concentration is high
enough to allow insulin dimer formation [40]. The requirement
for proper folding of the self-associated dimer prior to B25C
disulfide bond formation is inferred from the results of insulin’s
Figure 4. Assessing the stability of the B25C-dimer compared to HI. A: DSC of HI and the B25C-dimer. B: ThT fibrillation assay of 0.3 mM
B25C-dimer (grey diamonds) and 0.6 mM HI (black diamonds) with incubation at 37uC and vigorous shaking as described in ‘‘Methods’’. Both samples
contained 7 mM phosphate adjusted to pH 7.4.
doi:10.1371/journal.pone.0030882.g004
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cysteine scan. Although cysteine substitutions in 60% of insulin’s
positions resulted in expression in yeast, only B25C substitution led
solely to dimer formation. In fact, the pulse-chase experiment
reported here for the B25C-dimer demonstrated that insulin is
indeed associated into dimers during expression and this
association likely occurs early in the secretory pathway.
It is believed that it is the monomeric form of insulin that binds
to the insulin receptor even though the receptor forms a dimer and
therefore in principle could bind the HI-dimer [9]. In spite of large
efforts the structure of the complex between insulin and its
receptor is as of yet unavailable and many aspects of insulin
binding to its receptor are still unclear. Still much information
about the binding is available from other experiments
[2,24,27,45,50]. It is well known that B25F is important for
binding of insulin to its receptor [46,51] and replacement of Phe
with a Cys could be a factor in loss of binding. The receptor
binding affinity had decreased from picomolar affinity observed
for HI to nanomolar affinity for B25C-NEM confirming the
importance of the B25 position for receptor binding. Remarkably,
affinity for B25C-NEM was still 250 times higher than that of the
B25C-dimer. One possible explanation for the binding observed
for the B25C-dimer is, that small amounts of impurities (below
detection limits) resembling the monomeric form were responsible
for the binding. Another explanation involves alternative binding
of the dimer. One binding theory involves cooperative binding of
two monomeric insulin molecules thus suggesting that two insulin
molecules bind at the same time [50,52]. This theory involves two
binding sites, the classical binding site and the second binding site.
The classical binding site mainly consist of positions in the C-
terminal end of the B-chain and hydrophobic residues located in
the B-chain’s a-helix together with the C-terminal end of the A-
chain buried beneath the C-terminus of the B-chain. The second
binding site with lower binding affinity [50], consisting of A13L and
B17L, is located in the hexamer forming surface. In the B25C-dimer
the classical binding site is not accessible to binding; both because of
the overlap between the dimer forming surface and the binding
surface, but also because it is believed that binding of insulin to the
receptor involves a shift in the C-terminal end of the B-chain
exposing the hydrophobic residues involved in binding. This is not
possible in the dimer form [53–56]. Obstruction of the classical
binding site by removal of the first four amino acids in the A-chain
(desA1-4) was shown to decrease binding affinities to 0.014%
relative to HI [57] and fixation of the C-terminal end of the B-chain
in SCI resulted in a loss of in vivo activity [55]. In contrast, the second
binding site is still fully exposed and available for receptor binding.
To explain B25C-dimer receptor affinity and lipogenesis results by
binding exclusively to the second binding site would necessitate that
binding solely to this binding site leads to receptor activation, and
this has still not been shown. Regardless of which explanation for
the B25C-dimer insulin receptor binding is correct, it is clear that
insulin dimer is not able to bind to the insulin receptor with the same
affinity as the insulin monomer. This supports the hypothesis that it
is the monomeric form of insulin that is responsible for high affinity
interaction with insulin receptor.
The stability of the B25C-dimer became evident during
conversion of the expressed precursor to the mature insulin
analogue. The compact structure achieved during dimer
formation likely prevents proteases from accessing the cleavage
site. The C-terminal of the B-chain is known to be prone to
protease degradation [58]. It is also the only part of insulin
known to form b-strand structure. Comprehensive analysis of
binding motives recognised by proteases based on .1500 3D
structures showed that proteases with a few exceptions recognize
extended b-strand conformations [59]. B25C-dimer hinders the
access to the b-strand structure so the enhanced stability against
ALP will most likely also reflect enhanced stability against other
proteases.
The stability against fibrillation was also markedly improved for
the B25C-dimer compared to HI. It has been suggested that
hexamer formation during storage in secretory granules protects
insulin against fibrillation in vivo [48] and this is often exploited
when formulating insulin analogues for clinical use by addition of
zinc [10]. The ThT assay results with the B25C-dimer supported
that fibrillation only occurs through the monomeric form as no
fibrillation was seen for the dimer. Thus, it is clear that a stable
dimeric form is sufficient to stabilize insulin against fibrillation and
denaturation. This is also supported by the higher stability of the
B25C-dimer compared to HI hexamer as seen in the DSC results.
Thus, it is possible to generate an insulin dimer which is
sufficiently stable against denaturation and fibrillation under
stressed conditions such as high temperature making the
hexameric form redundant in protection against denaturation
and fibrillation. Stabilizing the insulin dimer formation, will
however result in limited receptor binding affinity. The evolu-
tionary solution to this fine balance between stability and receptor
binding is the formation of insulin hexamers. In the insulin
hexamer, the relatively weak insulin dimer interaction is stabilized
by zinc-induced association of three insulin dimers while allowing
for sufficient concentration of insulin monomer at low concentra-
tions without zinc and thus ensuring high affinity receptor binding.
This system has been preserved through evolution of most
vertebrate species. The exception to this rule is found in guinea
pigs insulin that has a mutation in the B10 position from a
histidine residue to an aspartate residue and is therefore not
capable of forming zinc induced hexamers. Its inability to form
dimers was also shown by AUC [60]. It is believed that removal of
the selective constraints associated with the ability to oligomerize
has allowed for additional mutations to compensate for the loss in
stability associated with loss in oligomerization. The monomeric
form of guinea pig insulin is stabilized by replacement of
hydrophobic residues on the surface (involved in oligomerization)
with hydrophilic residues [61]. These introduced mutations,
however, lead to reduced potency [62], which is compensated
by significantly increased level of insulin receptors in guinea pigs
[63].
In this paper, we describe a novel covalent insulin dimer that is
structurally identical to the self-association dimer of human insulin
and further associates into a hexamer in the presence of zinc
similarly to HI. We used this covalent dimer to directly investigate
the structure-function relationships of insulin oligomerization to
stability and receptor binding. This covalent dimer did not bind to
the insulin receptor. However, significant improvements in
stability of B25C-dimer relative to HI were demonstrated by
markedly slower processing of the precursor with ALP, an almost
40uC increase in Tm, more than 44 kJ/mol increase in DH in
DSC measurements and no fibrillation in ThT assay. Our results
underline that the dimerization of insulin is responsible for insulin
stability, while the monomeric form is required for this hormone’s
activity.
Supporting Information Legends
Figure S1 Positions in the dimer forming surface with
Ca to Ca distance ,10 A˚. The two B-chains in the dimer from
PDB file 1MSO are shown in grey with the positions B12(purple),
B13(cyan), B24(blue), B25(pink), B26(yellow) shown with the
respective distances between the position in each of the B-chains.
(TIF)
Novel Covalently Linked Insulin Dimer
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30882
Figure S2 The UV chromatogram (215 nm) of partially
purified B25C precursor. The LC/MS analyses of the pool
after partial purification of B25C precursors using cation exchange
chromatography showed that two precursors, peak 1 and peak 2,
were found after expression. The masses for both peaks
corresponded to a B25C-dimer linked by a disulfide bond.
(TIF)
Figure S3 Pulse chase experiment of the B25C-dimer.
The covalently linked B25C-dimer is seen as a strong band
between the 14.3 kDa and 21.5 kDa marker. Unprocessed
precursor containing the leader is seen for the dimer as a band
at the 30 kDa marker for the samples treated with PNGase.
(TIF)
Figure S4 Characterization of by-product. A: Total ion
count chromatogram of reduced by-product. B: MS/MS in source
fragmentation spectrum of peak with a mass equal to containing
single chain insulin (A-chain+B-chain-H2O(18 Da)). The b-ions
were identified from all fragments in black. The fragments in gray
were identified by either an a-ion in the N-terminal or y-ions in the
C-terminal. The MS/MS analyses showed the by-product to be a
result of ALP’s transpeptidase activity, where a peptide bond
between B29 and A1 was formed. ALP is known not only to work
as a protease but also as a transpeptidase [64]. Linking of the
B-chain’s C-terminal to the A-chain’s N-terminal by a peptide
bond was also observed before using trypsin another transpepti-
dase [55].
(TIF)
Figure S5 Sedimentation Velocity experiments illustrat-
ing the self-association abilities of the B25C-dimer
compared to HI. A: In the absence of zinc ions. B: In the
presence of increasing amount of zinc ions. The B25C-dimer had
a typical pattern for a reversible self-association, qualitatively
similar to HI both in the absence and presence of zinc ions.
(TIF)
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